A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database
TAEs constitute a small but significant fraction of PPI-related AEs. This study highlights the need for cautious long-term use of PPIs and further research to understand the underlying mechanisms and risk factors. Clinicians should be aware of the potential tumor risks associated with prolonged PPI treatment.
Authors
- Dandan Duan (ORCID: https://orcid.org/0000-0001-5145-9864)
- Shuxun Wei (ORCID: https://orcid.org/0000-0003-1467-5079)
- Caie Wang
- Yajun Zhang
- Qian-Yu Tian
Institutions
- Second Military Medical University (CN)
- JiangSu Armed Police General Hospital (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- Chinese People's Armed Police Force
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-19
- DOI
- https://doi.org/10.3389/fphar.2024.1524903
- Citations
- 2
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.70